Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Enveric Biosciences, Inc.AMRH · Entity 8193 | Chief Executive Officer | February 05, 2019 | February 05, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Enveric Biosciences, Inc.
Report date February 05, 2019 · Filed February 05, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,079,953 |
Reported balance
After 2019-02-05 transaction · row 1
1 source rowRow 1 · 2019-02-05 · Other · Acquired 986,777 · Balance 1,079,953 F1: Represents shares issued to the Reporting Person by the Issuer as payment of an earn-out in connection with the Issuer's acquisition of a wholly-owned subsidiary in March 2017, of which the Reporting Person had been an employee and shareholder. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares issued to the Reporting Person by the Issuer as payment of an earn-out in connection with the Issuer's acquisition of a wholly-owned subsidiary in March 2017, of which the Reporting Person had been an employee and shareholder.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 05, 2019 Filed Feb 5, 2019 21:19 UTC | Enveric Biosciences, Inc. AMRH · Entity 8193 | OtherCommon Stock | 986,777 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-19-002484 · form4.xml · nonDerivative · entry 1 Kelton Brent · CIK 0001727392 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,079,953 F1 · price: Represents shares issued to the Reporting Person by the Issuer as payment of an earn-out in connection with the Issuer's acquisition of a wholly-owned subsidiary in March 2017, of which the Reporting Person had been an employee and shareholder. Read SEC document |
| September 12, 2018 Filed Sep 14, 2018 20:22 UTC | Enveric Biosciences, Inc. AMRH · Entity 8193 | GrantOption (Right to Buy) · Derivative | 250,000 | $0.00 Strike: $1.45 | $0.00 |
DisclosureSEC source: 0000921895-18-002602 · form410211002kel_09142018.xml · derivative · entry 2 Kelton Brent · CIK 0001727392 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires not disclosed F1 · derivative.exercise_date: The options vest on the first anniversary of the grant date. The options will expire on the sixth anniversary of the grant date. F1 · derivative.expiration_date: The options vest on the first anniversary of the grant date. The options will expire on the sixth anniversary of the grant date. Read SEC document |
| February 09, 2018 Filed Feb 13, 2018 01:04 UTC | Enveric Biosciences, Inc. AMRH · Entity 8193 | OtherCommon Stock | 85,003 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000921895-18-000526 · form410211002kel_02132018.xml · nonDerivative · entry 1 Kelton Brent · CIK 0001727392 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,176 F1 · price: Represents shares issued to the Reporting Person by the Issuer as payment of an earn-out in connection with the Issuer's acquisition of a wholly-owned subsidiary in March 2017, of which the Reporting Person had been an employee and shareholder. Read SEC document |
| December 26, 2017 Filed Jan 11, 2018 23:15 UTC | Enveric Biosciences, Inc. AMRH · Entity 8193 | GrantOption (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $3.00 | $0.00 |
DisclosureSEC source: 0000921895-18-000133 · form410211002_01112018.xml · derivative · entry 2 Kelton Brent · CIK 0001727392 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2022-12-26 F1 · derivative.exercise_date: The Option vests as follows: (a) as to 33,333 shares of common stock of the Issuer ("Stock), on December 26, 2018, (b) as to a further 33,333 shares of Stock, on December 26, 2019, and (c) as to the remaining 33,334 shares of Stock, on December 26, 2020. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.